A Phase 1 Study of ATX-559 in Advanced Solid Tumors

Study Description

A First-in-Human Study of an Oral Drug (ATX-559) for Advanced or Metastatic Solid Tumors

Study Details

Registry ID:

NCT06625515

Conditions:

Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer

Phase:

Phase 1

Target Enrollment:

17 participants

Start Date:

October 11, 2024

Healthy Volunteers:

No

Study Locations (8 sites)

• Sarah Cannon Research Institute
  Nashville, TennesseeUnited States, United States
• SCRI Oncology Partners
  Nashville, TennesseeUnited States, United States
• The University of Texas MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• NEXT Oncology
  San Antonio, TexasUnited States, United States
• Stephenson Cancer Center at OU Medicine
  Oklahoma City, OklahomaUnited States, United States
• University of Oklahoma Health Sciences
  Oklahoma City, OklahomaUnited States, United States
• University of Colorado Cancer Center - Anschutz Medical Campus,
  Aurora, ColoradoUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →